STEP-HFpEF
To evaluate the effect of semaglutide (GLP-1) in patients with obesity and chronic HFpEF on heart failure disease-specific symptoms, health status and quality of life, when compared with placebo
- Stadium
- klaar
- Middel
- Semaglutide
- Populatie
- Hartfalen
- Fase
- III
- First Patient In
- 7 april 2021
- Last Patient In
- 1 maart 2022
- Last Patient Last Visit
- 19 april 2023
National Lead
dr. P van der Meer
Cardioloog
Studiedirecteur
dr. C.A. da Fonseca
Cardioloog
Contact Kantoor
